Clinical Trial

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

Study acronym: RAMP
Completed
View on ClinicalTrials.gov →
Summary
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
Protocol Amendment History 4 changes
critical Trial completed 2026-06-05
notable Enrollment reduced: 111 -> 53 participants 2026-06-05
notable Primary completion pushed: 2026-05 -> 2026-05-31 2026-06-05
minor Completion pushed: 2026-05 -> 2026-05-31 2026-06-05
Trial Details
NCT Number NCT07043803
Lead Sponsor University of Pittsburgh
Collaborators: National Center for Advancing Translational Sciences (NCATS), University of Pittsburgh Medical Center
Conditions Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
Enrollment 53 participants
Start Date 2025-07-16
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04